

Jonathan N Townend

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5210852/jonathan-n-townend-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

76
papers

2,767
citations

27
h-index

52
g-index

90
ext. papers

3,333
ext. citations

5.2
avg, IF

4.77
L-index

#	Paper	IF	Citations
76	Risk for subsequent hypertension and cardiovascular disease after living kidney donation: is it clinically relevant?. <i>CKJ: Clinical Kidney Journal</i> , 2022 , 15, 644-656	4.5	1
75	The characteristics of mitral regurgitation: Data from patients admitted following acute myocardial infarction. <i>Data in Brief</i> , 2021 , 39, 107451	1.2	1
74	Changes in left ventricular structure and function associated with renal transplantation: a systematic review and meta-analysis. <i>ESC Heart Failure</i> , 2021 , 8, 2045-2057	3.7	3
73	Improving the diagnosis of heart failure in patients with atrial fibrillation. <i>Heart</i> , 2021 , 107, 902-908	5.1	3
72	Cardiovascular Effects of Unilateral Nephrectomy in Living Kidney Donors at 5 Years. <i>Hypertension</i> , 2021 , 77, 1273-1284	8.5	5
71	Screening for occult coronary artery disease in potential kidney transplant recipients: time for reappraisal?. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 2472-2482	4.5	
70	Sudden cardiac death in chronic renal disease: aetiology and risk reduction strategies. <i>Nephrology Dialysis Transplantation</i> , 2021 , 36, 1386-1388	4.3	2
69	Acute Presentation of Structural Valve Degeneration in a Transcatheter Heart Valve (Sapien XT) at 7.5 Years; Successful Redo TAVR With a Sapien 3 Ultra. <i>CJC Open</i> , 2021 , 3, 383-386	2	1
68	Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease: A Randomized, Open-Label Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 , 16, 1491-1501	6.9	2
67	Mitral Regurgitation Following Acute Myocardial Infarction Treated by Percutaneous Coronary Intervention-Prevalence, Risk factors, and Predictors of Outcome. <i>American Journal of Cardiology</i> , 2021 , 157, 22-32	3	1
66	Coronary flow velocity reserve and inflammatory markers in living kidney donors. <i>International Journal of Cardiology</i> , 2020 , 320, 141-147	3.2	3
65	Clinical Potential of Targeting Fibroblast Growth Factor-23 and Klotho in the Treatment of Uremic Cardiomyopathy. <i>Journal of the American Heart Association</i> , 2020 , 9, e016041	6	11
64	Defining Myocardial Abnormalities Across the Stages of Chronic Kidney Disease: A Cardiac Magnetic Resonance Imaging Study. <i>JACC: Cardiovascular Imaging</i> , 2020 , 13, 2357-2367	8.4	9
63	Changes in Blood Pressure and Arterial Hemodynamics following Living Kidney Donation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020 , 15, 1330-1339	6.9	4
62	Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 2497-2508	27.4	35
61	Early effects of kidney transplantation on the heart - A cardiac magnetic resonance multi-parametric study. <i>International Journal of Cardiology</i> , 2019 , 293, 272-277	3.2	15
60	Comparison of Routine Versus Selective Glycoprotein IIb/IIIa Inhibitors Usage in Primary Percutaneous Coronary Intervention (from the British Cardiovascular Interventional Society). <i>American Journal of Cardiology</i> , 2019 , 124, 373-380	3	3

59	Coronary microvascular dysfunction: a key step in the development of uraemic cardiomyopathy?. <i>Heart</i> , 2019 , 105, 1302-1309	5.1	14
58	What is the cause of hypotension? A rare complication of percutaneous coronary intervention of a chronic total occlusion: a case report. <i>European Heart Journal - Case Reports</i> , 2019 , 3, 1-5	0.9	2
57	Arterial stiffness in chronic kidney disease: a modifiable cardiovascular risk factor?. <i>Current Opinion in Nephrology and Hypertension</i> , 2019 , 28, 527-536	3.5	5
56	Myocardial characterization in pre-dialysis chronic kidney disease: a study of prevalence, patterns and outcomes. <i>BMC Cardiovascular Disorders</i> , 2019 , 19, 295	2.3	4
55	Results of Serial Myocardial Perfusion Imaging in End-Stage Renal Disease. <i>American Journal of Cardiology</i> , 2018 , 121, 661-667	3	0
54	Chronic kidney disease as a cardiovascular risk factor: lessons from kidney donors. <i>Journal of the American Society of Hypertension</i> , 2018 , 12, 497-505.e4		8
53	A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial. <i>American Heart Journal</i> , 2017 , 191, 37-46	4.9	10
52	MP387CARDIAC LIMITATION OCCURS EARLY IN CKD, AND CANNOT BE FULLY EXPLAINED BY ISCHAEMIA OR REDUCED LV COMPLIANCE AS MEASURED BY DIASTOLIC FUNCTION DURING EXERCISE. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, iii570-iii570	4.3	
51	MP392CARDIOPULMONARY EXERCISE TESTING DETECTS SUBCLINICAL CARDIAC LIMITATION TO EXERCISE IN EARLY STAGE CKD. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, iii572-iii572	4.3	
50	A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. <i>BMJ Open</i> , 2017 , 7, e015099	3	29
49	Transcatheter Aortic Valve Implantation With or Without Percutaneous Coronary Artery Revascularization Strategy: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	62
48	10 Cardiac alterations after renal transplant; controversies unravelled by cardiac mri. <i>Heart</i> , 2017 , 103, A6-A7	5.1	1
47	11 Cpex testing detects subclinical cardiac limitation to exercise in early stage ckd. <i>Heart</i> , 2017 , 103, A7.1-A7	5.1	
46	CKD Associated Cardiomyopathy: Molecular Mechanisms, Imaging Modalities, Disease Evolution and Interventions 2017 , 45-58		1
45	Cardiovascular Effects of Unilateral Nephrectomy in Living Kidney Donors. <i>Hypertension</i> , 2016 , 67, 368-78.5		66
44	Prognostic Utility of Calcium Scoring as an Adjunct to Stress Myocardial Perfusion Scintigraphy in End-Stage Renal Disease. <i>American Journal of Cardiology</i> , 2016 , 117, 1387-96	3	15
43	Mechanical effects of left ventricular midwall fibrosis in non-ischemic cardiomyopathy. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2016 , 18, 1	6.9	82
42	Results and lessons from the Spironolactone To Prevent Cardiovascular Events in Early Stage Chronic Kidney Disease (STOP-CKD) randomised controlled trial. <i>BMJ Open</i> , 2016 , 6, e010519	3	12

41	Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. <i>BMC Nephrology</i> , 2016 , 17, 127	2.7	83
40	Caveolin-1 single-nucleotide polymorphism and arterial stiffness in non-dialysis chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1140-4	4.3	7
39	Coronary Artery Calcium Assessment in CKD: Utility in Cardiovascular Disease Risk Assessment and Treatment?. <i>American Journal of Kidney Diseases</i> , 2015 , 65, 937-48	7.4	31
38	Diffuse interstitial fibrosis and myocardial dysfunction in early chronic kidney disease. <i>American Journal of Cardiology</i> , 2015 , 115, 1311-7	3	69
37	Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. <i>BMJ, The</i> , 2015 , 351, h4451	5.9	172
36	Phosphate: are we squandering a scarce commodity?. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, 163-8	4.3	5
35	37 Cardiovascular Effects of Unilateral Nephrectomy in Human Kidney Donors. <i>Heart</i> , 2015 , 101, A20.2-A21	3.1	3
34	Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. <i>Lancet Diabetes and Endocrinology</i> , 2015 , 3, 514-25	18.1	381
33	Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: A systematic review and meta-analysis of randomized trials. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2015 , 16, 599-613	3	12
32	Comparison of magnetic resonance feature tracking for systolic and diastolic strain and strain rate calculation with spatial modulation of magnetization imaging analysis. <i>Journal of Magnetic Resonance Imaging</i> , 2015 , 41, 1000-12	5.6	78
31	Endothelial nitric oxide synthase single nucleotide polymorphism and left ventricular function in early chronic kidney disease. <i>PLoS ONE</i> , 2015 , 10, e0116160	3.7	11
30	Defining the natural history of uremic cardiomyopathy in chronic kidney disease: the role of cardiovascular magnetic resonance. <i>JACC: Cardiovascular Imaging</i> , 2014 , 7, 703-14	8.4	68
29	Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): study protocol for a randomized controlled pilot trial. <i>Trials</i> , 2014 , 15, 158	2.8	6
28	Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25mg once daily in addition to routine care on mortality and cardiovascular outcomes versus	2.8	22
27	The EARNEST study: interarm blood pressure differences should also be recorded. <i>American Heart Journal</i> , 2014 , 168, e9	4.9	
26	Quantification of left ventricular interstitial fibrosis in asymptomatic chronic primary degenerative mitral regurgitation. <i>Circulation: Cardiovascular Imaging</i> , 2014 , 7, 946-53	3.9	67
25	Effect of A Reduction in glomerular filtration rate after NEphrectomy on arterial STiffness and central hemodynamics: rationale and design of the EARNEST study. <i>American Heart Journal</i> , 2014 , 167, 141-149.e2	4.9	15
24	Impaired circumferential and longitudinal myocardial deformation in early stage chronic kidney disease: the earliest features of uremic cardiomyopathy. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2013 , 15,	6.9	3

23	Effects of age and chronic kidney disease on regional aortic distensibility: a cardiovascular magnetic resonance study. <i>International Journal of Cardiology</i> , 2013 , 168, 4249-54	3.2	14
22	Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation. <i>American Journal of Kidney Diseases</i> , 2013 , 62, 615-32	7.4	57
21	Cardiovascular effects of sevelamer in stage 3 CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2013 , 24, 842-52	12.7	90
20	Arterial disease in chronic kidney disease. <i>Heart</i> , 2013 , 99, 365-72	5.1	97
19	Cytomegalovirus seropositivity is associated with increased arterial stiffness in patients with chronic kidney disease. <i>PLoS ONE</i> , 2013 , 8, e55686	3.7	26
18	Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: cause or association?. <i>Atherosclerosis</i> , 2012 , 223, 86-94	3.1	88
17	Aortic calcification and femoral bone density are independently associated with left ventricular mass in patients with chronic kidney disease. <i>PLoS ONE</i> , 2012 , 7, e39241	3.7	10
16	The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 447-54	3.8	43
15	Letter by Moody et al regarding article "Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction". <i>Circulation</i> , 2012 , 126, e62; author reply e64-5	16.7	
14	Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: a cardiac magnetic resonance study. <i>Heart</i> , 2012 , 98, 219-24	5.1	55
13	Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised controlled trial. <i>Trials</i> , 2011 , 12, 30	2.8	10
12	Serum phosphate but not pulse wave velocity predicts decline in renal function in patients with early chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2011 , 26, 2576-82	4.3	51
11	Does immunosuppressant medication lower blood pressure and arterial stiffness in patients with chronic kidney disease? An observational study. <i>Hypertension Research</i> , 2011 , 34, 113-9	4.7	12
10	The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. <i>Clinical Endocrinology</i> , 2010 , 73, 566-72	3.4	13
9	Republished paper: Arterial stiffness in chronic kidney disease: causes and consequences. <i>Postgraduate Medical Journal</i> , 2010 , 86, 560-6	2	14
8	Arterial stiffness in chronic kidney disease: causes and consequences. <i>Heart</i> , 2010 , 96, 817-23	5.1	104
7	Echocardiography in the potential heart donor. <i>Transplantation</i> , 2010 , 89, 894-901	1.8	39
6	Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. <i>American Journal of Cardiology</i> , 2010 , 106, 1505-11	3	47

- 5 The haemodynamic effects of adjunctive hormone therapy in potential heart donors: a prospective randomized double-blind factorially designed controlled trial. *European Heart Journal*, **2009**, 30, 1771-80^{9.5} 95
- 4 Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. *Journal of the American College of Cardiology*, **2009**, 54, 505-12 15.1 214
- 3 Upregulation of the nitric oxide-cGMP pathway in aged myocardium. *Circulation Research*, **2001**, 88, E48 15.7 1
- 2 Nitric oxide and cardiac autonomic control in humans. *Hypertension*, **2000**, 36, 264-9 8.5 136
- 1 Role of nitric oxide in the regulation of cardiovascular autonomic control. *Clinical Science*, **1999**, 97, 5-17 6.5 105